GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

As detailed in our previous updates, the IRA’s Medicare Drug Price Negotiation Program (the Negotiation Program or Program), ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Doctors at the University of Utah’s Moran Eye Center have reviewed cases of nine patients who developed vision problems while ...

Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new ...

People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why - There’s no direct link ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...